Anshul Thakral Biography and Net Worth

CEO of Fortrea

Anshul Thakral is Chief Executive Officer of Fortrea (Nasdaq: FTRE), having joined the company in August 2025. He also serves as a member of Fortrea’s Board of Directors.

Anshul has more than 25 years of experience in the CRO, pharmaceutical and biotech industries as a general manager, management consultant, commercial leader and entrepreneur. He served as Co-Founder and Chief Executive Officer of Launch Therapeutics since its founding in March 2022. From July 2016 to February 2022, Anshul served in increasing levels of seniority at PPD, from Global Head of PPD Biotech to Chief Commercial Officer and Executive Vice President of Peri- and Post-Approval Services at PPD. Before PPD, Anshul ran the global life sciences business unit at Gerson Lehrman Group (GLG) from March 2014 to June 2016 and served as a consultant at McKinsey & Company from August 2006 to March 2014, where he was an associate principal in the healthcare practice, counselling senior management and CEOs of global pharmaceutical and biotechnology companies.

Anshul currently serves on the Board of Directors of Orsini Specialty Pharmacy, a leader in pharmacy solutions for rare disease and complex therapy programs.

Anshul earned his Bachelor of Science and Master of Science in Engineering in Biomedical Engineering from Johns Hopkins University and his Master of Business Administration from the Wharton School at the University of Pennsylvania.

What is Anshul Thakral's net worth?: The estimated net worth of Anshul Thakral is at least $5.75 million as of August 5th, 2026. Mr. Thakral owns 316,797 shares of Fortrea stock worth more than $5,745,747 as of August 7th. This net worth estimate does not reflect any other assets that Mr. Thakral may own. Learn More about Anshul Thakral's net worth.
How do I contact Anshul Thakral?: The corporate mailing address for Mr. Thakral and other Fortrea executives is 8 Moore Drive, Durham, NC 27709, United States, . Fortrea can also be reached via phone at 877-495-0816 and via email at [email protected]. Learn More on Anshul Thakral's contact information.
Has Anshul Thakral been buying or selling shares of Fortrea?: During the last quarter, Anshul Thakral has sold $1,913,490.04 in Fortrea stock. Most recently, Anshul Thakral sold 99,869 shares of the business's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $19.16, for a transaction totalling $1,913,490.04. Following the completion of the sale, the chief executive officer now directly owns 316,797 shares of the company's stock, valued at $6,069,830.52. Learn More on Anshul Thakral's trading history.
Who are Fortrea's active insiders?: Fortrea's insider roster includes James Hanson (General Counsel), Jill McConnell (CFO), Peter Neupert (Director), Robert Parks (CAO), Thomas Pike (CEO & Chairman), Erin Russell (Director), and Anshul Thakral (CEO). Learn More on Fortrea's active insiders.
Are insiders buying or selling shares of Fortrea?: In the last twelve months, Fortrea insiders bought shares 3 times. They purchased a total of 72,354 shares worth more than $507,168.10. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 119,853 shares worth more than $2,100,366.97. The most recent insider tranaction occured on August, 5th when CEO Anshul Thakral sold 99,869 shares worth more than $1,913,490.04. Insiders at Fortrea own 0.7% of the company. Learn More about insider trades at Fortrea.
Information on this page was last updated on 8/5/2026.

Anshul Thakral Insider Trading History at Fortrea

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2026	Sell	99,869	$19.16	$1,913,490.04	316,797

Anshul Thakral Buying and Selling Activity at Fortrea

Fortrea Company Overview

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Today's Range

Now: $18.37

$17.58

$18.44

50 Day Range

MA: $17.42

$15.27

$20.70

2 Week Range

Now: $18.37

$6.07

$21.39

Volume

443,494 shs

Average Volume

1,531,269 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99